Here’s why Lucid Diagnostics (LUCD) declined in Q3

Minot Light Capital Partners, an investment management company, released its Q3 2025 investment letter. A copy of the letter ...
abc27

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

Report includes nearly 12,000 patients who underwent Lucid's EsoGuard ® Esophageal DNA Test on samples collected using its EsoCheck ® Esophageal Cell Collection Device Real-world data confirm ...
Seeking Alpha

Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic ...
Morningstar

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with ...
KTLA

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
Nasdaq

LUCID DIAGNOSTICS Earnings Preview: Recent $LUCD Insider Trading, Hedge Fund Activity, and More

LUCID DIAGNOSTICS ($LUCD) is expected to release its quarterly earnings data on Monday, March 24th before market open, per Finnhub. Analysts are expecting revenue of ...
Benzinga.com

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

According to Needham, Lucid Diagnostics Inc. (NASDAQ:LUCD) is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes. The Lucid Diagnostics ...
Nasdaq

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage ...
Crain's New York

Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors of esophageal cancer, a highly deadly cancer for which a diagnosis is ...
Seeking Alpha

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (LUCD) (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...
MarketWatch

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics ...